Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia

Alexandre Puissant, PhD, Nina Fenouille, PhD, Christopher F. Bassil, BA, Issam Ben-Sahra, PhD, Lina Benajiba, Gabriela Alexe, PhD, Azucena Ramos, Yana Pikman, MD, Michael R. Burgess, MD PhD, Qing Li, MD PhD, Frederic Luciano, PhD, Patrick Auberger, PhD, Ilene Galinsky, MSN, ANPc, Daniel J. DeAngelo, MD PhD, Richard M. Stone, MD, Archibald S. Perkins, MD PhD, Kevin Shannon, MD, Michael T. Hemann, PhD, Kimberly Stegmaier, MD

Blood (2016) 128 (22): 523.

https://doi.org/10.1182/blood.V128.22.523.523

Published: 2016

Journal Articles

Response and Resistance to Bromodomain Inhibition in AML Driven By Hyperactive Ras Signaling

Benjamin Huang, MD, Eugene Hwang, Anica M. Wandler, PhD, Ben Powell, PhD, Gideon Bollag, PhD, Kevin Shannon, MD

Blood (2016) 128 (22): 1654.

https://doi.org/10.1182/blood.V128.22.1654.1654

Published: 2016

Journal Articles

Resistant T-Cell Acute Lymphoblastic Leukemias That Emerge after In Vivo Treatment with Dexamethasone Frequently Down-Regulate Glucocorticoid Receptor Protein Expression

Blood (2016) 128 (22): 753.

https://doi.org/10.1182/blood.V128.22.753.753

Published: 2016

Journal Articles

Identification of CKMT1B As a New Target in EVI1-Positive AML

Alexandre Puissant, PhD, Nina Fenouille, PhD, Christopher F. Bassil, BA, Issam Ben-Sahra, PhD, Gabriela Alexe, PhD, Lina Benajiba, Azucena Ramos, Yana Pikman, MD, Michael R. Burgess, MD PhD, Ilene Galinsky, ANP, Daniel J. DeAngelo, MD PhD, Richard M. Stone, MD, Kevin Shannon, MD, Michael T. Hemann, PhD, Kimberly Stegmaier, MD

Blood (2015) 126 (23): 3674.

https://doi.org/10.1182/blood.V126.23.3674.3674

Published: 2015

Journal Articles

Aberrant Hematopoietic Stem Cell Function in Mice Haploinsufficient for a 2 Mb Deletion of Chromosome 5A3 Syntenic to a Region of Human 7q22 Frequently Deleted in Myelodysplastic Syndromes

Jasmine C. Wong, PhD, Kelley Weinfurtner, BA, Pilar Alzamora, Scott C. Kogan, MD, Michael R. Burgess, MD PhD, Yan Zhang, PhD, Joy Nakitandwe, PhD, Jing Ma, PhD, Jinjun Cheng, MB, MS, Shann-Ching Chen, PhD, Johanna Flach, Damien Reynaud, PhD, Emmanuelle Passegue, PhD, James R Downing, MD, Kevin Shannon, MD

Blood (2014) 124 (21): 3247.

https://doi.org/10.1182/blood.V124.21.3247.3247

Published: 2014

Journal Articles

Preclinical Efficacy of MEK Inhibition in Nras Mutant Acute Myeloid Leukemia

Michael R. Burgess, MD PhD, Eugene Hwang, BA, Ari J Firestone, PhD, Tannie Huang, MD, Jin Xu, PhD, Johannes Zuber, MD, Natacha Bohin, BS, Tiffany Wen, BS, Scott C. Kogan, MD, Kevin M. Haigis, PhD, Scott W. Lowe, PhD, Kevin Shannon, MD, Qing Li, MD PhD

Blood (2014) 124 (21): 3753.

https://doi.org/10.1182/blood.V124.21.3753.3753

Published: 2014

Journal Articles

Loss of Wild-Type Kras is Associated with Enhanced Fitness and Increased Mitogen-Activated Protein Kinase Pathway Addiction in K-Ras G12D Acute Myeloid Leukemia

Michael R. Burgess, MD PhD, Eugene Hwang, BA, Anica M. Wandler, PhD, Saurabh Asthana, PhD, Elizabeth M. Davis, BS, Michelle M. Le Beau, PhD, Barry Taylor, PhD, Kevin Shannon, MD

Blood (2014) 124 (21): 907.

https://doi.org/10.1182/blood.V124.21.907.907

Published: 2014

Journal Articles

Biochemical and Functional Analysis of Novel KRAS Insertions in MPN and Other Cancers

Yasmine N White, Aditi Bagchi, Jessica Van Ziffle, PhD, Gideon Bollag, PhD, Chao Zhang, PhD, David S Dickens, MD, Mignon L. Loh, MD, Kevin Shannon, MD, Ari J Firestone, PhD

Blood (2014) 124 (21): 2207.

https://doi.org/10.1182/blood.V124.21.2207.2207

Published: 2014

Journal Articles

Preclinical Testing Of a PI3K Inhibitor In T Lineage Leukemia: Target Validation and Notch1/Myc Down-Regulation In Drug Resistant Clones

Monique Dail, PhD, Jason Wong, Jessica Lawrence, Daniel O'Connor, Joy Nakitandwe, PhD., Shann-Ching Chen, PhD, Keiko Akagi, Leslie Lee, Jon C. Aster, MD, PhD, Warren S. Pear, MD, PhD, Deepak Sampath, PhD, James R. Downing, MD, Kevin Shannon, MD

Blood (2013) 122 (21): 2677.

https://doi.org/10.1182/blood.V122.21.2677.2677

Published: 2013

Journal Articles

Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia

Elliot Stieglitz, MD, Y. Lucy Liu, MD, PhD, Peter D. Emanuel, MD, Robert P. Castleberry, MD, Todd Michael Cooper, Kevin Shannon, MD, Mignon L. Loh, MD

Blood (2013) 122 (21): 1526.

https://doi.org/10.1182/blood.V122.21.1526.1526

Published: 2013

Journal Articles

Ras-Pathway Inhibition With Targeted Therapies Abrogates Self-Renewal In Acute Myelogenous Leukemia

Rebecca S. LaRue, PhD, Hanh Nguyen, Karen Sachs, Nurul Azyan Mohd Hassan, Ernesto Diaz-Flores, PhD, Susan K. Rathe, Aaron G. Sarver, Ph.D., Sean C. Bendall, Ngoc A. Ha, Miechaleen D. Diers, B.S., Garry P. Nolan, PhD, Kevin Shannon, MD, Zohar Sachs, MD, PhD, David A. Largaespada, PhD

Blood (2013) 122 (21): 819.

https://doi.org/10.1182/blood.V122.21.819.819

Published: 2013

Journal Articles

Combination of a MEK Inhibitor, AZD6244, and Dual PI3K/mTOR Inhibitor, NVP-BEZ235: An Effective Therapeutic Strategy for Acute Myeloid Leukemia

Hongtao Liu, MD, PhD, Ernesto Diaz-Flores, PhD, Xavier Poiré, MD, Olatoyosi Odenike, MD, Greg Koval, MS, Greg Malnassy, MS, Pamela Ihonor, MS, Yanming Zhang, MD, Michelle M. Le Beau, PhD, Kevin Shannon, MD, Wendy Stock, MD

Blood (2010) 116 (21): 3978.

https://doi.org/10.1182/blood.V116.21.3978.3978

Published: 2010

Journal Articles

Akt Activation Is Important In KRAS-Mediated Multistep Leukemogenesis

Ashley F. Ward, MD, Angell Shieh, MD, Emily Rose Harding-Theobald, BA, Gideon Bollag, PhD, Kevin Shannon, MD

Blood (2010) 116 (21): 4200.

https://doi.org/10.1182/blood.V116.21.4200.4200

Published: 2010

Journal Articles

Oncogene Withdrawal Selectively Alters Phosphoprotein States and Shifts Differentiation Status In Myeloid Leukemia Subpopulations

Zohar Sachs, MD, PhD, Ernesto Diaz-Flores, PhD, Miechaleen D Diers, Karen Sachs, Sean C Bendall, PhD, Harris G Fienberg, Susan K Rathe, Garry P. Nolan, Ph.D., Kevin Shannon, MD, David Largaespada, PhD

Blood (2010) 116 (21): 3160.

https://doi.org/10.1182/blood.V116.21.3160.3160

Published: 2010

Journal Articles

Combinations of Kinase Inhibitors May Be An Effective Therapeutic Strategy for Acute Myeloid Leukemia (AML) with MLL-AF9 Expression.

Xavier Poiré, MD, Ernesto Diaz-Flores, PhD, Rachel Joy Bergerson, Dorie Sher, B.S., Olatoyosi Odenike, MD, Kevin Shannon, MD, David Largaespada, PhD, Wendy Stock, MD

Blood (2009) 114 (22): 1032.

https://doi.org/10.1182/blood.V114.22.1032.1032

Published: 2009

Journal Articles

PI3 Kinase, Phospholipase C (PLC)-γ, and RasGRPs Act Cooperatively to Activate the Ras-Extracellular-Related Kinase (ERK) Pathway in Response to Cytokines in Normal and Kras Mutant Myeloid Cells.

Ernesto Diaz-Flores, PhD, Hana Leah Goldschmidt, BA, Philippe Depeille, Ph.D, Victor Ng, BA, Jeroen Roose, Assistant, Professor, Kevan Shokat, Ph.D., Benjamin S. Braun, MD, PhD, Kevin Shannon, MD

Blood (2009) 114 (22): 2512.

https://doi.org/10.1182/blood.V114.22.2512.2512

Published: 2009

Journal Articles

Treatment with a MEK Inhibitor Improves Myeloproliferation, Anemia and Survival in a Mouse Model of CMML and JMML.

Natalya Lyubynska, Jennifer Lauchle, MD, Kevin Shannon, MD, Benjamin S. Braun, MD, PhD

Blood (2009) 114 (22): 966.

https://doi.org/10.1182/blood.V114.22.966.966

Published: 2009

Journal Articles

Germline Mutations in CBL Cause a Predisposition to Juvenile Myelomonocytic Leukemia.

Blood (2009) 114 (22): 310.

https://doi.org/10.1182/blood.V114.22.310.310

Published: 2009

Journal Articles

Biology, Therapy, and Resistance of Myeloid Malignancies Initiated by Hyperactive Ras.

Kevin Shannon, MD

Blood (2008) 112 (11): sci-9.

https://doi.org/10.1182/blood.V112.11.sci-9.sci-9

Published: 2008

Journal Articles

Kras G12D Expression in Hematopoietic Stem/Progenitor Cells Initiates T Cell Acute Lymphoblastic Leukemia/Lymphoma.

Monique Dail, PhD, Qing Li, MD, PhD, Jennifer Lauchle, MD, Andrew McDaniel, Doris Kim, Keiko Akagi, PhD, Linda Wolff, PhD, Nancy Jenkins, PhD, Neil Copeland, PhD, Kevin Shannon, MD

Blood (2007) 110 (11): 153.

https://doi.org/10.1182/blood.V110.11.153.153

Published: 2007

NARROW

Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia

Response and Resistance to Bromodomain Inhibition in AML Driven By Hyperactive Ras Signaling

Resistant T-Cell Acute Lymphoblastic Leukemias That Emerge after In Vivo Treatment with Dexamethasone Frequently Down-Regulate Glucocorticoid Receptor Protein Expression

Identification of CKMT1B As a New Target in EVI1-Positive AML

Aberrant Hematopoietic Stem Cell Function in Mice Haploinsufficient for a 2 Mb Deletion of Chromosome 5A3 Syntenic to a Region of Human 7q22 Frequently Deleted in Myelodysplastic Syndromes

Preclinical Efficacy of MEK Inhibition in Nras Mutant Acute Myeloid Leukemia

Loss of Wild-Type Kras is Associated with Enhanced Fitness and Increased Mitogen-Activated Protein Kinase Pathway Addiction in K-Ras G12D Acute Myeloid Leukemia

Biochemical and Functional Analysis of Novel KRAS Insertions in MPN and Other Cancers

Preclinical Testing Of a PI3K Inhibitor In T Lineage Leukemia: Target Validation and Notch1/Myc Down-Regulation In Drug Resistant Clones

Mutations In GATA2 Are Rare In Juvenile Myelomonocytic Leukemia

Ras-Pathway Inhibition With Targeted Therapies Abrogates Self-Renewal In Acute Myelogenous Leukemia

Combination of a MEK Inhibitor, AZD6244, and Dual PI3K/mTOR Inhibitor, NVP-BEZ235: An Effective Therapeutic Strategy for Acute Myeloid Leukemia

Akt Activation Is Important In KRAS-Mediated Multistep Leukemogenesis

Oncogene Withdrawal Selectively Alters Phosphoprotein States and Shifts Differentiation Status In Myeloid Leukemia Subpopulations

Combinations of Kinase Inhibitors May Be An Effective Therapeutic Strategy for Acute Myeloid Leukemia (AML) with MLL-AF9 Expression.

PI3 Kinase, Phospholipase C (PLC)-γ, and RasGRPs Act Cooperatively to Activate the Ras-Extracellular-Related Kinase (ERK) Pathway in Response to Cytokines in Normal and Kras Mutant Myeloid Cells.

Treatment with a MEK Inhibitor Improves Myeloproliferation, Anemia and Survival in a Mouse Model of CMML and JMML.

Germline Mutations in CBL Cause a Predisposition to Juvenile Myelomonocytic Leukemia.

Biology, Therapy, and Resistance of Myeloid Malignancies Initiated by Hyperactive Ras.

Kras G12D Expression in Hematopoietic Stem/Progenitor Cells Initiates T Cell Acute Lymphoblastic Leukemia/Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only